Glaucoma Market Size in the 7MM was around USD 4.2 billion in 2022, estimates DelveInsight

The Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2022-2032). Furthermore, launching various multiple- Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics"

The Glaucoma market report provides current treatment practices, emerging drugs, Glaucoma market share of the individual therapies, current and forecasted Glaucoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Glaucoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Glaucoma market.

Key Takeaways from the Glaucoma Market Research Report
• In 2021, the least revenue generating class for the treatment of glaucoma was selective EP2 receptor agonists, which generated a total revenue of USD 25 million in the 7MM.
• According to DelveInsight's analysis, among the gender-specific prevalent cases, females are affected more with glaucoma than male.
• The leading Glaucoma Companies include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others
• Promising Glaucoma Pipeline Therapies include Durysta (Bimatoprost SR), Xelpros (latanoprost ophthalmic emulsion) 0.005%, Tapcom/DE-111 (Tafluprost/timolol maleate), Glanatec, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, AILAMIDE/ SJP-0125, Aibeta/SJP-0135, Travatan Z (travoprost ophthalmic solution) 0.004%, Eybelis Ophthalmic Solution 0.002% (DE-117,Omidenepag isopropyl), Vyzulta (BOL-303259-X), Rocklatan, Rhopressa, Zioptan (Tafluprost), DuoTrav PQ (Travoprost/timolol), and others.

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma Market Size- https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Overview
Glaucoma is a disease that damages the eye's optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.

Glaucoma Epidemiology Segmentation in the 7MM
• Total Glaucoma Diagnosed Prevalence
• Glaucoma Type-specific Diagnosed Prevalence
• Glaucoma Age-specific Diagnosed Prevalence
• Glaucoma Gender-specific Diagnosed Prevalence

Download the report to understand which factors are driving Glaucoma Epidemiology Trends @ Glaucoma Epidemiological Insights- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Glaucoma Treatment Landscape
• The US FDA accepted the New Drug Application for the lead product candidate, PDP-716 (0.35% brimonidine tartrate), which has the potential to be the first once-daily brimonidine to enter the market for the treatment of glaucoma. The drug contains brimonidine which is one of the most commonly used treatments of glaucoma and ocular hypertension. Recently SPARC entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialization of PDP-716 and SDN-037.
• In September 2022, company's lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase III pivotal trial. The company is on track for New Drug Application (NDA) filing, with the FDA in Q1 2023. TC-002 is a preservative-free latanoprost ophthalmic solution that is being developed by TearClear for the treatment of glaucoma. TearClear is the first and only company to develop products that deliver preservative-free drops to the eye while maintaining BAK preserved formulations in the bottle.
• DE-130A (latanoprost) is an ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. In October 2022, filing of latanoprost was accepted by European Medicines Agency (EMA) for review of application for marketing authorization in glaucoma.

Glaucoma Treatment Market
The mainstay of the treatment for Glaucoma is to improve quality of life. There are therapies that are undergoing investigational analysis for the same. Treatment approach for the steroid-induced secondary glaucoma goes similar to that of open-angle glaucoma and can include options like eye drops, and surgical approaches. At times, whenever possible, discontinuation of steroids or moving to Non-steroidal anti-inflammatory drugs is recommended. For patients with neovascular glaucoma, it is often required to control the ocular pressure along with the treatment of underlying cause which is leading to the growth of new blood vessels. The treatment is mainly focused on the improvement of QoL through the proper management of intraocular pressure (IOP) and treating the causative condition. This helps in prevention of further deterioration of the glaucoma condition and can be helpful in avoiding vision loss. Proper identification of the type of glaucoma is important so that treatment can be progressed accordingly.

Glaucoma Market Dynamics
The dynamics of Glaucoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies and devices during the forecast period of 2023-2032. Treatment options for Glaucoma are rapidly expanding. However, still there is no cure available.

To know more about Glaucoma Treatment options, visit @ Glaucoma Drugs- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Emerging Drugs

• PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
PDP-716 is a novel, once-a-day formulation of Brimonidine developed using SPARC's TearActTM Technology for treatment of Glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine which is one of the most commonly used treatments of glaucoma and ocular hypertension. The company has recently released the topline results for the Phase III clinical trials for PDP-716 in 2021.

• TC-002 : TearClear
TC-002 is a preservative-free latanoprost ophthalmic solution that is being developed by TearClear for the treatment of glaucoma. TearClear is the first and only company to develop products that deliver preservative-free drops to the eye while maintaining BAK preserved formulations in the bottle.

Glaucoma Market Outlook
Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery or a combination of any of these.

Learn more about the Glaucoma Pipeline Therapies in clinical trials @ Glaucoma Market Landscape- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glaucoma Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Glaucoma Companies- Allergan (NYSE: AGN), Sun Pharma Advanced Research Company Limited (NYSE: SPARC), Santen Pharmaceutical Co., Ltd (NYSE: SNPHY), D.Western Therapeutics Institute (NYSE: DWTI), Kowa Ltd., Alcon (NYSE: ALC), Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd. (NYSE: OTSKF), TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma (NYSE: OCUP), Sylentis, Nicox Opthalmics, Perrigo Company (NYSE: PRGO), Bausch and Lomb (NYSE: BLCO), Ono Pharmaceutical, Novartis (NYSE: NVS), Merck & Co (NYSE: MRK), Aerie Pharmaceuticals (NYSE: AERI), Ube Industries, and others
• Glaucoma Pipeline Therapies- Durysta (Bimatoprost SR), Xelpros (latanoprost ophthalmic emulsion) 0.005%, Tapcom/DE-111 (Tafluprost/timolol maleate), Glanatec, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, AILAMIDE/ SJP-0125, Aibeta/SJP-0135, Travatan Z (travoprost ophthalmic solution) 0.004%, Eybelis Ophthalmic Solution 0.002% (DE-117,Omidenepag isopropyl), Vyzulta (BOL-303259-X), Rocklatan, Rhopressa, Zioptan (Tafluprost), DuoTrav PQ (Travoprost/timolol), and others.
• Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
• Glaucoma Market Access and Reimbursement, Unmet Needs, and Emerging Drugs

Discover more about Glaucoma Drugs in development @ Glaucoma Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Glaucoma Market Overview at a Glance
4. Executive Summary of Glaucoma
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Marketed Products
9. Emerging Therapies
10. Glaucoma: Seven Major Market Analysis
11. KOL Views
12. Glaucoma Market Drivers
13. Glaucoma Market Barriers
14. SWOT Analysis
15. Unmet Needs
16. Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Get in touch with our Business executive @ Glaucoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Published Important Links-

https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.